Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

被引：0
|
作者：
A. B. Sanchez Spitman
D. J. A. R. Moes
H. Gelderblom
V. O. Dezentje
J.J. Swen
H. J. Guchelaar
机构：
[1] Leiden University Medical Center,Leiden Network for Personalised Therapeutics, Department of Clinical Pharmacy and Toxicology
[2] Leiden University Medical Center,Department of Medical Oncology
[3] Reinier de Graaf,Department of Medical Oncology
来源：
European Journal of Clinical Pharmacology | 2017年 / 73卷
关键词：
Tamoxifen; Endoxifen; and ;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1589 / 1598
页数：9
相关论文
共 50 条
  • [1] Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
    Spitman, A. B. Sanchez
    Moes, D. J. A. R.
    Gelderblom, H.
    Dezentje, V. O.
    Swen, J. J.
    Guchelaar, H. J.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (12) : 1589 - 1598
  • [2] EFFECT OF CYP3A4*22, CYP3A5*3 AND CYP3A COMBINED GENOTYPES ON ENDOXIFEN SERUM CONCENTRATIONS IN BREAST CANCER PATIENTS USING TAMOXIFEN.
    Spitman, A. B. Sanchez
    Moes, D. -J. A.
    Gelderblom, H.
    Dezentje, V. O.
    Swen, J. J.
    Guchelaar, H. -J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S48 - S48
  • [3] Effect of CYP3A4* 22, CYP3A5* 3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
    Moes, D. J. A. R.
    Swen, J. J.
    den Hartigh, J.
    van der Straaten, T.
    van der Heide, J. J. Homan
    Sanders, J. S.
    Bemelman, F. J.
    de Fijter, J. W.
    Guchelaar, H. J.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (02):
  • [4] Effect of CYP3A4*22 and CYP3A5 Combined Genotypes on Tacrolimus Disposition in Heart Transplantation
    Vu, A.
    Page, R. L.
    Roscoe, N.
    Lindenfeld, J. A.
    Aquilante, C. L.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S115 - S116
  • [5] Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5
    Cook, CS
    Berry, LM
    Kim, DH
    Burton, EG
    Hribar, JD
    Zhang, LM
    [J]. DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) : 1344 - 1351
  • [6] Effect of CYP3A5 genotype on the relationship between hepatic CYP3A activity and CYP3A4 and CYP3A5 mRNA expression
    Kolwankar, D
    Ho, H
    Ethell, B
    Vuppalanchi, R
    Marri, SR
    Wrighton, SA
    Jones, DR
    Hall, SD
    [J]. DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [7] Comparative drug metabolism by CYP3A4 and CYP3A5
    Huang, WL
    Lin, YS
    Dai, Y
    Totah, RA
    Calamia, JC
    Thummel, KE
    [J]. DRUG METABOLISM REVIEWS, 2003, 35 : 187 - 187
  • [8] APPLICATION OF THE CYP3A4 SELECTIVE MECHANISM-BASED INACTIVATOR CYP3CIDE TO DELINEATE CYP3A4 AND CYP3A5 CONTRIBUTIONS TO THE METABOLISM OF CYP3A CLEARED DRUGS
    Tseng, Elaine
    Walsky, Robert L.
    Luzietti, Rick
    Harris, Jennifer
    Kosa, Rachel E.
    Zientek, Michael A.
    Goosen, Theunis C.
    Obach, R. Scott
    [J]. DRUG METABOLISM REVIEWS, 2014, 45 : 77 - 77
  • [9] Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
    Saiz-Rodriguez, Miriam
    Almenara, Susana
    Navares-Gomez, Marcos
    Ochoa, Dolores
    Roman, Manuel
    Zubiaur, Pablo
    Koller, Dora
    Santos, Maria
    Mejia, Gina
    Borobia, Alberto M.
    Rodriguez-Antona, Cristina
    Abad-Santos, Francisco
    [J]. BIOMEDICINES, 2020, 8 (04)
  • [10] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism
    McGraw, Joseph
    Cherney, Mitchell
    Bichler, Katherine
    Gerhardt, Armin
    Nauman, Mirielle
    [J]. TOXICOLOGY LETTERS, 2019, 315 : 9 - 13
12345